Clinical Trial

Disease: Multiple myeloma, MM (NCT05308875)

Disease info:

Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the centre of most bones. Multiple myeloma is characterised by abnormalities in a type of white blood cells known as the plasma cells. These abnormal cells multiply out of control, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumours within the bone, causing bone pain and an increased risk of fractures.

Frequency:
Multiple myeloma occurs in approximately 4 per 100,000 people per year; there are currently about 100,000 affected individuals in the United States.
Official title:
Clinical Study of the Safety and Efficacy of Non-viral Site-directed Integrated PD1-BCMA-CART in Adult Treatment of Relapsed or Refractory Multiple Myeloma
Who:

Wei Li, PhD,  +8618621670308,    adamweili@126.com

Partners:

The First Affiliated Hospital of Zhengzhou University

Locations:

China, Henan

Study start:
Apr. 1, 2022
Enrollment:
9
Gene editing method:
Undisclosed
Type of edit:
Knock-out
Gene:
PDCD1 (encodes PD-1)
Delivery method:
Undisclosed - Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status:

Description

Using gene editing, chimeric antigen receptors recognising B cell maturation antigen BCMA were integrated into subject self-derived T cells to obtain a large number of BCMA-CART by in vitro amplification, and BCMA-CART back into the subjects could identify and kill myeloma cells in the subjects. This open-label, dose-escalation study was designed to evaluate the safety and anti-tumour efficacy of PD1-BCMA-CART in the treatment of relapsed or refractory multiple myeloma.

Last updated: May. 2, 2022
close
Search CRISPR Medicine